INmune Bio Announces Results Of Additional Blinded Interim Analysis Of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation Between EMACC And CDR-SB Endpoints
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. announced positive results from an interim analysis of its Phase 2 Alzheimer's Disease trial, showing a strong correlation between the novel cognitive measure EMACC and the established CDR-SB endpoint.
September 17, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio Inc. reported promising interim results from its Phase 2 Alzheimer's Disease trial, showing a strong correlation between the novel EMACC measure and the CDR-SB endpoint, potentially boosting investor confidence.
The announcement of positive interim results in a Phase 2 trial for Alzheimer's Disease is likely to boost investor confidence in INmune Bio. The strong correlation between EMACC and CDR-SB, a recognized endpoint, suggests potential efficacy of the treatment, which could lead to positive market reactions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100